加载中
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
前收盘价
US$12.67
+US$0.28 · +2.26%
盘中时间采用ET。市场数据可能有所延迟。
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
日内区间
当前US$12.67
52周区间
当前US$12.67
盘中时间采用ET。市场数据可能有所延迟。
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
日内区间
当前US$12.67
52周区间
当前US$12.67
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 9998.6万 USD | 7990.6万 USD | 6542.1万 USD | 4552万 USD | 4518.3万 USD |
| 销货成本 | 2276.6万 USD | 2082.1万 USD | 1729.9万 USD | 1302.7万 USD | 1174.8万 USD |
| 毛利 | 7722万 USD | 5908.5万 USD | 4812.2万 USD | 3249.3万 USD | 3343.5万 USD |
| 研究与开发 | 2788.8万 USD | 2365.3万 USD | 2077.8万 USD | 2194.6万 USD | 1821.1万 USD |
| 销售、一般及管理费用 | 6567万 USD | 5710.3万 USD | 5451.8万 USD | 5134.1万 USD | 3896.1万 USD |
| 营业费用 | 9355.8万 USD | 8075.6万 USD | 7529.6万 USD | 7328.7万 USD | 5717.2万 USD |
| 利息收入 | 281.6万 USD | 302.4万 USD | 305万 USD | 157.8万 USD | 44.8万 USD |
| 利息支出 | 745.7万 USD | 879.8万 USD | 851.7万 USD | 752.9万 USD | 741万 USD |
| 折旧和摊销 | 194.8万 USD | 176.9万 USD | 160.5万 USD | 298.7万 USD | 29.6万 USD |
| 营业利润 | −1633.8万 USD | −2167.1万 USD | −2717.4万 USD | −4079.4万 USD | −2373.7万 USD |
| 净利润 | −2146.5万 USD | −2714.1万 USD | −3295.6万 USD | −4708.2万 USD | −3608万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.25
上涨空间 59.83%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
